A proportion of diffuse intrinsic pontine gliomas (DIPG) harbor alterations that predict sensitivity to MEK inhibition; however, resistance can quickly occur via MEK1/2 mutation that can be overcome with addition of dasatinib, providing a therapeutic option. The gene discussed is MAP2K1; the disease is diffuse intrinsic pontine glioma.